CANCER-RELATED PROBLEM/CONDITION
Clinical trials for CANCER-RELATED PROBLEM/CONDITION explained in plain language.
Never miss a new study
Get alerted when new CANCER-RELATED PROBLEM/CONDITION trials appear
Sign up with your email to follow new studies for CANCER-RELATED PROBLEM/CONDITION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Phone app trial offers new hope for easing cancer Survivors' exhaustion
Symptom relief Recruiting nowThis study is testing a mobile app called EnergyPoints that teaches and guides users through acupressure to help manage cancer-related fatigue and sleep problems. The trial will involve 180 adult cancer survivors who will use the app at home for six weeks while wearing a Fitbit t…
Matched conditions: CANCER-RELATED PROBLEM/CONDITION
Phase: NA • Sponsor: 5 Point App, Inc. • Aim: Symptom relief
Last updated Mar 27, 2026 12:40 UTC
-
Wakefulness drug tested to combat debilitating cancer fatigue
Symptom relief Recruiting nowThis study is testing if a medication called modafinil can help reduce severe fatigue and thinking problems (often called 'chemo brain') in people with advanced cancer. About 40 patients will take either the drug or a placebo pill for one week to see if it makes a difference. The…
Matched conditions: CANCER-RELATED PROBLEM/CONDITION
Phase: PHASE1, PHASE2 • Sponsor: Ottawa Hospital Research Institute • Aim: Symptom relief
Last updated Mar 13, 2026 15:06 UTC
-
Cancer patients skip clinic trips with home blood tests in new study
Knowledge-focused Recruiting nowThis study is testing whether cancer patients can safely check their own blood counts at home during chemotherapy. It aims to see if this approach reduces unnecessary trips to the hospital, saves time and money, and improves patients' quality of life. The study involves 265 patie…
Matched conditions: CANCER-RELATED PROBLEM/CONDITION
Sponsor: Pomeranian Medical University Szczecin • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC